Tibet Rhodiola Pharmaceutical Holding Co (600211) — Capital Reinvestment Ratio
Tibet Rhodiola Pharmaceutical Holding Co (600211) has a Capital Reinvestment Ratio of 0.02x as of December 2025, meaning it reinvests 0% of its operating cash flow (CN¥297.86 Million) in capital expenditures (CN¥4.98 Million). Check Tibet Rhodiola Pharmaceutical Holding Co (600211) tangible equity ratio to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Tibet Rhodiola Pharmaceutical Holding Co Capital Reinvestment Ratio (1999–2025)
This chart tracks Tibet Rhodiola Pharmaceutical Holding Co's Capital Reinvestment Ratio across 25 annual periods. For the full cash flow conversion analysis, see how efficiently does Tibet Rhodiola Pharmaceutical Holding Co generate cash.
Annual Capital Reinvestment Ratio for Tibet Rhodiola Pharmaceutical Holding Co (1999–2025)
Year-by-year Capital Reinvestment Ratio for Tibet Rhodiola Pharmaceutical Holding Co from 1999 to 2025. See Tibet Rhodiola Pharmaceutical Holding Co free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.02x | CN¥1.03 Billion | CN¥15.96 Million | ▼ -58.9% |
| 2024 | 0.04x | CN¥994.79 Million | CN¥37.60 Million | ▲ +88.6% |
| 2023 | 0.02x | CN¥1.08 Billion | CN¥21.69 Million | ▼ -83.5% |
| 2022 | 0.12x | CN¥837.38 Million | CN¥101.96 Million | ▼ -89.5% |
| 2021 | 1.16x | CN¥366.53 Million | CN¥425.58 Million | ▲ +124.7% |
| 2020 | 0.52x | CN¥428.17 Million | CN¥221.29 Million | ▲ +416.4% |
| 2019 | 0.10x | CN¥489.59 Million | CN¥49.00 Million | ▲ +23.9% |
| 2018 | 0.08x | CN¥289.22 Million | CN¥23.37 Million | ▼ -98.8% |
| 2017 | 6.65x | CN¥91.46 Million | CN¥607.98 Million | ▲ +17152.2% |
| 2016 | 0.04x | CN¥250.21 Million | CN¥9.64 Million | ▼ -51.6% |
| 2015 | 0.08x | CN¥133.93 Million | CN¥10.66 Million | ▼ -34.8% |
| 2013 | 0.12x | CN¥279.22 Million | CN¥34.12 Million | ▲ +55.4% |
| 2012 | 0.08x | CN¥56.20 Million | CN¥4.42 Million | ▼ -58.9% |
| 2011 | 0.19x | CN¥12.09 Million | CN¥2.31 Million | ▼ -85.9% |
| 2010 | 1.36x | CN¥1.90 Million | CN¥2.58 Million | ▲ +555.4% |
| 2009 | 0.21x | CN¥17.88 Million | CN¥3.70 Million | ▼ -7.5% |
| 2008 | 0.22x | CN¥21.46 Million | CN¥4.80 Million | ▼ -52.7% |
| 2006 | 0.47x | CN¥33.63 Million | CN¥15.90 Million | ▲ +26.5% |
| 2005 | 0.37x | CN¥18.92 Million | CN¥7.07 Million | ▼ -42.4% |
| 2004 | 0.65x | CN¥26.90 Million | CN¥17.45 Million | ▲ +33.8% |
| 2003 | 0.48x | CN¥47.20 Million | CN¥22.88 Million | ▼ -84.4% |
| 2002 | 3.11x | CN¥32.85 Million | CN¥102.14 Million | ▼ -39.7% |
| 2001 | 5.15x | CN¥15.47 Million | CN¥79.72 Million | ▼ -10.6% |
| 2000 | 5.76x | CN¥20.55 Million | CN¥118.45 Million | ▼ -79.5% |
| 1999 | 28.15x | CN¥2.25 Million | CN¥63.25 Million | — |